CSS
NWBO

Cubist Systematic Strategies’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Cubist Systematic Strategies’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-14,400
Closed -$106K – 2298
2015
Q1 		$106K Buy
+14,400
New +$96.9K 0.01% 1653

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CWM
CIBC World Markets New York $20.8B AUM

Cubist Systematic Strategies's NWBO Position: Q2 2015 in Review

Cubist Systematic Strategies sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2015, closing a stake of 14,400 shares — an estimated $106K sold.

Cubist Systematic Strategies first reported a position in NWBO in Q1 2015 and held it in 1 quarter. The position peaked at $106K in Q1 2015. 83 funds tracked by Wall St. Rank hold NWBO as of Q2 2015.

  • Cubist Systematic Strategies reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2015 after selling out during the quarter.
  • Cubist Systematic Strategies sold 14,400 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2015, an estimated $106K.
  • Cubist Systematic Strategies first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2015 and held it in 1 quarter.
  • Cubist Systematic Strategies's Northwest Biotherapeutics, Inc. Common stock position peaked at $106K in Q1 2015.
  • 83 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2015.

Based on Cubist Systematic Strategies's 13F filing for Q2 2015, filed 14 Aug 2015.